Exploring the cucurbitacins in neurofibromatosis: Molecular mechanisms and pharmacological potential

Neurofibromatosis (NF) operates as a hereditary tumor-predisposition disease that primarily results from NF1 and NF2 gene mutations which cause the formation of noncancerous and cancerous tumors that affect the nervous system. The dysregulated operation of crucial signaling pathways, which include JAK/STAT and PI3K/Akt/mTOR and Ras/MAPK, has a major effect on how tumors start growing and their following development. The field of targeted therapeutics has made progress yet the existing long-term treatment options remain insufficient which drives the search for new therapeutic compounds that can target multiple pathways. Cucurbitacins which belong to the class of highly oxygenated tetracyclic triterpenoids that plants from the Cucurbitaceae family produce have gained recognition as effective anticancer agents because they exhibit powerful anti-proliferative effects and induce cell death and block cellular signaling pathways. Recent experiments show that cucurbitacins, which include cucurbitacin B and E and I, inhibit tumor cell growth through their control of cell cycle checkpoints and their activation of mitochondrial apoptosis and their suppression of STAT3 and PI3K/Akt pathways and their generation of reactive oxygen species. The processes directly relate to neurofibromatosis tumor biology since schwannoma and neurofibroma tumors grow because of permanent activation of survival pathways. The development of treatments faces significant challenges which include toxic effects and poor drug availability and insufficient clinical studies. The study presents an overview of cucurbitacins in neurofibromatosis by discussing their molecular mechanisms and drug properties and potential therapeutic applications and upcoming research for targeted delivery and clinical studies.